Pharmacoeconomics of HIV-infection

2018

Регуляторные исследования и экспертиза лекарственных средств, Vol 0, Iss 4, Pp 58-63 (2018)

Ever since the first registrations of HIV-infections at the territory of the Russian Federation there was started a great process on arrangement and, subsequently, development of anti-HIV system. It should be noted, that increase of HIV screening and number of patients on antiretroviral treatment are the most important features of the system. Nevertheless, experts note the continuing growth of the size of infected population and, that is more important, the escape of HIV-epidemics from the groups with risk behaviors to the general population, therefore it is necessary to further increase the effectiveness of activities against HIV-spreading. In particular, it is necessary to use more rational (in the context of both the effectiveness, safety and cost) in present settings medical technologies. Pharmacoeconomic analysis is an appropriate instrument for these challenges. However pharmacoeconomic analysis within HIV-infection, like within all other disease areas, has some planning and conducting specialties. We formulated some key aspects of pharmacoeconomic analysis within HIV-infection: need for modelling; use of several criteria (virological, immunological, clinical and epidemiological); consideration of adherence to the therapy; consideration of complications costs; consideration of indirect costs.

article

Russian

Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’), 2018.

human immunodeficiency virus (hiv), antiretroviral therapy (art), pharmacoeconomic analysis, modeling, cost analysis, effectiveness analysis, effectiveness criteria, budget impact analysis, adherence, epidemics, burden of the disease, вирус иммунодефицита человека (вич), антиретровирусная терапия (арт), фармакоэкономический анализ, моделирование, анализ затрат, анализ эффективности, критерии эффективности, анализ «влияния на бюджет», приверженность, эпидемия, бремя заболевания, Medicine (General), R5-920